{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:08:09Z","timestamp":1791331689463,"version":"4.3.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2021YFS0170"],"award-info":[{"award-number":["2021YFS0170"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ijantimicag.2023.106872","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T11:09:29Z","timestamp":1685185769000},"page":"106872","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Real-world effectiveness of ceftazidime\/avibactam versus polymyxin B in treating patients with carbapenem-resistant Gram-negative bacterial infections"],"prefix":"10.1016","volume":"62","author":[{"given":"Junyan","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9224-5895","authenticated-orcid":false,"given":"Jian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenggong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cejun","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoju","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106872_bib0001","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1473-3099(14)70850-3","article-title":"Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus","volume":"15","author":"Nation","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106872_bib0002","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/antibiotics9020071","article-title":"Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales","volume":"9","author":"Vena","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2023.106872_bib0003","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2018.07.010","article-title":"Evaluation of ceftazidime\/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa","volume":"15","author":"Rodr\u00edguez-N\u00fa\u00f1ez","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106872_bib0004","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106872_bib0005","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2147\/IDR.S350976","article-title":"Ceftazidime\/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant Pseudomonas aeruginosa Infection","volume":"15","author":"Chen","year":"2022","journal-title":"Infect Drug Resist"},{"issue":"4","key":"10.1016\/j.ijantimicag.2023.106872_bib0006","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1007\/s40121-021-00542-3","article-title":"Ceftazidime-Avibactam-Based Versus Tigecycline-Based Regimen for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae-Induced Pneumonia in Critically Ill Patients","volume":"10","author":"Shi","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"1","key":"10.1016\/j.ijantimicag.2023.106872_bib0007","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13756-020-00829-z","article-title":"Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012\u20132016)","volume":"9","author":"Zhang","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"issue":"1","key":"10.1016\/j.ijantimicag.2023.106872_bib0008","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.01026-20","article-title":"Ceftolozane\/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa","volume":"6","author":"Teo","year":"2021","journal-title":"mSphere"},{"issue":"1","key":"10.1016\/j.ijantimicag.2023.106872_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.00042-16","article-title":"Carbapenem-Resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia","volume":"30","author":"Hsu","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2023.106872_bib0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13756-016-0115-6","article-title":"Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia","volume":"5","author":"Suwantarat","year":"2016","journal-title":"Antimicrob Resist Infect Control"},{"issue":"1","key":"10.1016\/j.ijantimicag.2023.106872_bib0011","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12941-020-00355-1","article-title":"In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015\u20132017)","volume":"19","author":"Ko","year":"2020","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"3","key":"10.1016\/j.ijantimicag.2023.106872_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106284","article-title":"Antibiotic strategies and clinical outcomes for patients with carbapenem-resistant Gram-negative bacterial bloodstream infection","volume":"57","author":"Qu","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106872_bib0013","series-title":"Performance standards for antimicrobial susceptibility testing, 30th edition (M100-S30)","year":"2020"},{"issue":"9","key":"10.1016\/j.ijantimicag.2023.106872_bib0014","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1093\/cid\/ciaa121","article-title":"Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints","volume":"71","author":"Satlin","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.ijantimicag.2023.106872_bib0015","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America Guidance on the Treatment of AmpC \u03b2-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106872_bib0016","article-title":"Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria","author":"Pintado","year":"2022","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"issue":"3","key":"10.1016\/j.ijantimicag.2023.106872_bib0017","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jmii.2022.02.001","article-title":"Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms","volume":"55","author":"Sy","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106872_bib0018","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01882-17","article-title":"Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network","volume":"62","author":"Zhang","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106872_bib0019","series-title":"Institute of Antibiotics, Huashan Hospital","year":"2022"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106872_bib0020","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1089\/mdr.2017.0061","article-title":"Risk Factors for Carbapenem-Resistant Klebsiella pneumoniae Infection: A Meta-Analysis","volume":"24","author":"Liu","year":"2018","journal-title":"Microb Drug Resist"},{"issue":"11","key":"10.1016\/j.ijantimicag.2023.106872_bib0021","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01045-17","article-title":"Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijantimicag.2023.106872_bib0022","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1186\/s12879-021-06153-0","article-title":"vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016\u20132018)","volume":"21","author":"Pi\u00e9rard","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.ijantimicag.2023.106872_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2019.08.020","article-title":"Emergence of ceftazidime\/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China","volume":"26","author":"Zhang","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.ijantimicag.2023.106872_bib0024","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/cid\/ciab390","article-title":"Will Ceftazidime-Avibactam Replace Polymyxins in Asia?","volume":"73","author":"Tan","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106872_bib0025","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/mdr.2018.0398","article-title":"In Vitro Antimicrobial Susceptibility Differences Between Carbapenem-Resistant KPC-2-Producing and NDM-1-Producing Klebsiella pneumoniae in a Teaching Hospital in Northeast China","volume":"26","author":"Lin","year":"2020","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.ijantimicag.2023.106872_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2021.05.079","article-title":"Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia","volume":"109","author":"Hakeam","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106872_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.780940","article-title":"Efficacy of Ceftazidime-Avibactam Versus Polymyxin B and Risk Factors Affecting Clinical Outcomes in Patients With Carbapenem-Resistant Klebsiella pneumoniae Infections a Retrospective Study","volume":"12","author":"Fang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.ijantimicag.2023.106872_bib0028","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02320-19","article-title":"Ceftazidime-Avibactam To Treat Life-Threatening Infections by Carbapenem-Resistant Pathogens in Critically Ill Mechanically Ventilated Patients","volume":"64","author":"Tsolaki","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.ijantimicag.2023.106872_bib0029","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.ijantimicag.2023.106872_bib0030","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/8755122520934726","article-title":"Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem\/Cilastatin-Relebactam to Target Klebsiella pneumoniae Carbapenemase-Producing Enterobacterales","volume":"36","author":"Hayden","year":"2020","journal-title":"J Pharm Technol"},{"issue":"8","key":"10.1016\/j.ijantimicag.2023.106872_bib0031","doi-asserted-by":"crossref","first-page":"e00211","DOI":"10.1128\/AAC.00211-17","article-title":"Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model","volume":"61","author":"Lin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106872_bib0032","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14737167.2021.1964960","article-title":"Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant Klebsiella pneumoniae in Colombia","volume":"22","author":"Var\u00f3n-Vega","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"9","key":"10.1016\/j.ijantimicag.2023.106872_bib0033","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106872_bib0034","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jgar.2021.04.015","article-title":"Continuous infusion, therapeutic drug monitoring and outpatient parenteral antimicrobial therapy with ceftazidime\/avibactam: a retrospective cohort study","volume":"26","author":"Goncette","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2023.106872_bib0035","series-title":"Critical Care Nephrology (Second Edition)","first-page":"309","article-title":"Chapter 56: Multiple Organ Dysfunction Syndrome","author":"Piccinni","year":"2009"},{"issue":"9","key":"10.1016\/j.ijantimicag.2023.106872_bib0036","first-page":"1336","article-title":"Serial evaluation of the MODS, SOFA and LOD scores to predict ICU mortality in mixed critically ill patients","volume":"91","author":"Khwannimit","year":"2008","journal-title":"J Med Assoc Thai"},{"issue":"1","key":"10.1016\/j.ijantimicag.2023.106872_bib0037","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000521288","article-title":"Charlson Comorbidity Index: A Critical Review of Clinimetric Properties","volume":"91","author":"Charlson","year":"2022","journal-title":"Psychother Psychosom"},{"issue":"5","key":"10.1016\/j.ijantimicag.2023.106872_bib0038","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2044.2007.04999.x","article-title":"Comparison of Acute Physiology and Chronic Health Evaluation (APACHE) II score with organ failure scores to predict hospital mortality","volume":"62","author":"Ho","year":"2007","journal-title":"Anesthesia"},{"issue":"7","key":"10.1016\/j.ijantimicag.2023.106872_bib0039","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.21037\/apm-21-338","article-title":"Predictors of mortality in patients with carbapenem-resistant Klebsiella pneumoniae infection: a meta-analysis and a systematic review","volume":"10","author":"Qian","year":"2021","journal-title":"Ann Palliat Med"},{"issue":"8","key":"10.1016\/j.ijantimicag.2023.106872_bib0040","doi-asserted-by":"crossref","first-page":"8617","DOI":"10.21037\/apm-21-932","article-title":"Predictors of mortality in adult patients with methicillin-resistant Staphylococcus aureus bloodstream infection: a meta-analysis and systematic review","volume":"10","author":"Ju","year":"2021","journal-title":"Ann Palliat Med"},{"issue":"5","key":"10.1016\/j.ijantimicag.2023.106872_bib0041","doi-asserted-by":"crossref","first-page":"R116","DOI":"10.1186\/cc2373","article-title":"Assessment of six mortality prediction models in patients admitted with severe sepsis and septic shock to the intensive care unit: a prospective cohort study","volume":"7","author":"Arabi","year":"2003","journal-title":"Crit Care"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:45:49Z","timestamp":1760377549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923001516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0924857923001516"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106872","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness of ceftazidime\/avibactam versus polymyxin B in treating patients with carbapenem-resistant Gram-negative bacterial infections","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106872","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106872"}}